Funding And Financial PositionTheriva has a cash runway into the fourth quarter of 2025, supported by an additional $7.5 million raised from equity financing.

Regulatory And Clinical TrialsTheriva has begun planning a pivotal P3 study to evaluate the same combo of VCN-01 + gem/nab vs. gem/nab alone in metastatic PDAC, with plans to request an End-of-Phase 2 meeting with the FDA to discuss the proposed design.

Research And DevelopmentVCN-01 has the potential to resensitize tumors to other therapies by degrading tough stromal tissue, which could be advantageous in treating pancreatic cancer.

Bears Say

Clinical Trial ResultsThe overall data from the P2b pancreatic cancer study was mixed and unimpressive, particularly because the key measure of median overall survival did not meet expectations.

Clinical Trial UncertaintyThe path forward for VCN-01 is unclear, with uncertainty about whether it will progress to a Phase 3 study or if the dosing needs further exploration.

Stock PerformanceThe shares of Theriva Biologics experienced a significant drop of 40% due to the unimpressive data results and concurrent equity financing.

Theriva Biologics News

Theriva Biologics reports Q2 EPS ($1.93) vs. ($10.72) last year

“We are highly encouraged by the progress we’ve made so far in the first half of 2025,” said...

12d ago

TOVX

Theriva Biologics sees cash runway into 1Q26

Cash and cash equivalents totaled $12.1 million as of June 30, 2025, compared to $11.6 million as of...

12d ago

TOVX

Theriva Biologics Faces Financial Risks Amid Shifting Trade Policies and Tariffs

Theriva Biologics, Inc. (TOVX) has disclosed a new risk, in the Capital Markets category. Theriva Biologics, Inc. faces...

12d ago

TOVX

Theriva Biologics Reports Promising Trial Results and Financials

Theriva Biologics, Inc. ( ($TOVX) ) has released its Q2 earnings. Here is a breakdown of the information...

12d ago

TOVX

Theriva Biologics Sets 2025 Shareholder Meeting Date

Theriva Biologics ( ($TOVX) ) just unveiled an announcement. Theriva Biologics, Inc. announced the date for its 2025...

2M ago

TOVX

Theriva Biologics Announces At-The-Market Stock Offering

Theriva Biologics ( ($TOVX) ) just unveiled an announcement. On June 20, 2025, Theriva Biologics, Inc. announced the...

2M ago

TOVX

Theriva Biologics Presents Promising VCN-01 Study Results

Theriva Biologics ( ($TOVX) ) has shared an announcement. Theriva Biologics announced the results of a Phase 1...

3M ago

TOVX

Theriva Biologics announces presentation of data from VCN-01 Phase 1 trial

Theriva Biologics (TOVX) announced the upcoming presentation of final clinical outcomes and safety data from the investigator sponsored...

3M ago

TOVX

Theriva Biologics reports Q1 EPS ($1.55) vs ($7.53) last year

“We have started 2025 with outstanding clinical progress,” said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics...

3M ago

TOVX

Theriva Biologics sees cash runway into 1Q26

Cash and cash equivalents totaled $10 million as of March 31, 2025, compared to $11.6 million as of...

3M ago

TOVX

Theriva Biologics Completes $7.5 Million Public Offering

An update from Theriva Biologics ( ($TOVX) ) is now available. On May 8, 2025, Theriva Biologics completed...

4M ago

TOVX

Theriva Biologics downgraded to Hold from Buy at Maxim

Maxim downgraded Theriva Biologics (TOVX) to Hold from Buy. Published first on TheFly – the ultimate source for...

4M ago

TOVX

Theriva Biologics downgraded to Hold from Buy at Maxim

Maxim downgraded Theriva Biologics (TOVX) to Hold from Buy with no price target The firm cites the company...

4M ago

TOVX

Theriva Biologics prices 6.8M shares at $1.10 in public offering

Theriva Biologics (TOVX) announced the pricing of its “reasonable best efforts” public offering for the purchase and sale...

4M ago

TOVX

TOVX FAQ

What was Theriva Biologics’s price range in the past 12 months?

Theriva Biologics lowest stock price was $0.36 and its highest was $7.15 in the past 12 months.

What is Theriva Biologics’s market cap?

Theriva Biologics’s market cap is $4.09M.

When is Theriva Biologics’s upcoming earnings report date?

Theriva Biologics’s upcoming earnings report date is Nov 18, 2025 which is in 87 days.

How were Theriva Biologics’s earnings last quarter?

Theriva Biologics released its earnings results on Aug 11, 2025. The company reported -$1.93 earnings per share for the quarter, missing the consensus estimate of -$0.775 by -$1.155.

Is Theriva Biologics overvalued?

According to Wall Street analysts Theriva Biologics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Theriva Biologics pay dividends?

Theriva Biologics does not currently pay dividends.

What is Theriva Biologics’s EPS estimate?

Theriva Biologics’s EPS estimate is -0.38.

How many shares outstanding does Theriva Biologics have?

Theriva Biologics has 9,597,952 shares outstanding.

What happened to Theriva Biologics’s price movement after its last earnings report?

Theriva Biologics reported an EPS of -$1.93 in its last earnings report, missing expectations of -$0.775. Following the earnings report the stock price went up 13.514%.

Which hedge fund is a major shareholder of Theriva Biologics?

Currently, no hedge funds are holding shares in TOVX

Company Description

Theriva Biologics

Theriva Biologics (TOVX) is a biotechnology company focused on the development and commercialization of therapeutics for cancer and other diseases. The company's core products involve the use of oncolytic viruses and live microbial therapeutics to enhance the efficacy of existing treatments and improve patient outcomes. By leveraging innovative biologic technologies, Theriva Biologics aims to address unmet medical needs and offer new solutions in oncology and other therapeutic areas.